Abstract
Worldwide interest in biogenerics or biosimilars is gaining momentum. Since
Kalorama Information last visited the market for synthetic or recombinant
versions of natural biologic substances, including proteins such as enzymes or
antibodies four years ago, there has been much more worldwide involvement in
the development of the biogeneric arena.
The biological drug market is at a crossroads. Some of the biggest-selling
biological drugs developed during the first phase of the biotechnology
revolution in the 1980s, including human growth hormone (hGH) and insulin,
have lost patent protection or are set to lose patent protection in the US in
2007 and beyond. This opens up the market currently worth $40 billion and
growing at over 20% per year if the regulatory hurdles can be overcome.
Kalorama Information' s survey includes as part of its market analysis a
breakdown of generic replacements for:
- Drugs with Active patents
- Drugs with Expired patents
with this geographic breakdown:
In addition to market information, this report includes:
- Complete Overview
- Patent dates for Major Biopharmaceuticals
- Issues and Trends in the Industry
- Scientific Differences Between Biopharmaceuticals and Biogenerics
- Key Regulations Affecting this Market
- Company Profiles
As part of Kalorama Information' s trusted information gathering process, this
report is the result of both primary and secondary research. In addition to
exhaustive research, Key executives at biogeneric companies were consulted to
uncover key trends and develop models.
View Cart
